Update [tmco]
therapeutic use [topp]
Patients [podg]
ischaemic heart disease [dsyn]
Percutaneous [spco]
coronary [bpoc]
Revascularisation [topp]
abciximab [aapp, imft, phsu]
ReoPro [aapp, phsu]
R- [spco]
Antibody [aapp, celc, imft]
fragment [ftcn]
Dose [qnco]
arrested [dsyn]
Platelet aggregation [celf]
leukocyte adhesion [celf]
binding [ftcn]
Glycoprotein IIb/IIIa [aapp, imft, rcpt]
Vitronectin [aapp, bacs]
Mac-1 Receptor [aapp, imft, rcpt]
abciximab [aapp, imft, phsu]
mg kg [qnco]
bolus infusion [topp]
Plus [qlco]
kg/min [cnce]
Efficacy [qlco]
tirofiban [orch, phsu]
Reducing [qlco]
Composite [qlco]
End Point [qlco]
Myocardial Infarction [dsyn]
Urgent [tmco]
Target vessel [blor]
Revascularisation [topp]
Double-Blind Study [resa]
Target [ftcn]
Patients [podg]
Scheduled [inpr]
Stent placement [topp]
Addition [ftcn]
effects [qlco]
treatment [ftcn]
abciximab [aapp, imft, phsu]
Observed [ftcn]
placebo-controlled [resa]
Maintained [ftcn]
Reduced [qlco]
Ischaemic [ftcn]
Complications [patf]
Relative [famg]
placebo [topp]
Observed [ftcn]
Range [qnco]
subgroups [virs]
Including [ftcn]
Age [orga]
Sex [orgf]
Body Weight [orga]
indication [idcn]
Revascularisation [topp]
Composite [qlco]
End Point [qlco]
Reduced [qlco]
Patients [podg]
Presenting [idcn]
Acute myocardial infarction [dsyn]
48 hours [tmco]
Duration [tmco]
Comparison [acty]
Fibrinolytic Therapy [topp]
stenting [medd]
Alone [qnco]
Trial [resa]
Reduced [qlco]
Requirement [ftcn]
Urgent [tmco]
Repeat [ftcn]
Revascularisation [topp]
Reduced [qlco]
Mortality [qnco]
Trial, Multicenter [resa]
Patients [podg]
Acute myocardial infarction [dsyn]
Myocardial Infarction [dsyn]
stenting [medd]
Alone [qnco]
Superior [spco]
Percutaneous Transluminal Coronary Angioplasty [topp]
stenting [medd]
Alone [qnco]
Inferior [spco]
Percutaneous Transluminal Coronary Angioplasty [topp]
abciximab [aapp, imft, phsu]
Large [qnco]
Multicenter Studies [resa]
Assent [cnce]
Efficacy [qlco]
Various [irda]
Ischaemic [ftcn]
endpoints [qlco]
abciximab [aapp, imft, phsu]
Combination [qlco]
Reduced [qlco]
Dose [qnco]
Tenecteplase [aapp, enzy, phsu]
Reteplase [aapp, enzy, phsu]
Compared [acty]
Fibrinolytic Drugs [phsu]
Alone [qnco]
TIMI Flow [clna]
Grade III [qlco]
90 Minutes [tmco]
Speed [qnco]
Trial [resa]
Patients [podg]
Received [qlco]
abciximab [aapp, imft, phsu]
Combination [qlco]
Alteplase [aapp, enzy, phsu]
Reteplase [aapp, enzy, phsu]
abciximab [aapp, imft, phsu]
Alone [qnco]
Seen [qlco]
Full [qlco]
Dose [qnco]
fibrinolytic [topp]
Alone [qnco]
Multicenter Study [resa]
Ischaemic [ftcn]
endpoints [qlco]
days [tmco]
Patients [podg]
Syndromes, Acute Coronary [dsyn]
Scheduled [inpr]
Revascularisation [topp]
End [spco]
Infusion [topp]
apparent [idcn]
Received [qlco]
abciximab [aapp, imft, phsu]
Bolus [topp]
48 hour [tmco]
Infusion [topp]
Received [qlco]
placebo [topp]
Aspirin [orch, phsu]
Heparin [bacs, carb, phsu]
adverse events [fndg]
abciximab [aapp, imft, phsu]
Bleeding [patf]
Complications [patf]
Thrombocytopenia [fndg]
Bleeding [patf]
Limited [ftcn]
Adhere [fndg]
Current [tmco]
Administration [ocac]
Protocols [inpr]
Treatment Costs [qnco]
Stent [medd]
Plus [qlco]
abciximab [aapp, imft, phsu]
Angioplasty [topp]
Plus [qlco]
abciximab [aapp, imft, phsu]
Group [idcn]
Stent [medd]
Plus [qlco]
placebo [topp]
Acquisition [acty]
Cost [qnco]
abciximab [aapp, imft, phsu]
abciximab [aapp, imft, phsu]
APPEAR [qlco]
Cost [qnco]
High Risk [qlco]
Patients [podg]
ELECTIVE [topp]
Percutaneous Coronary Revascularization [topp]
Low Risk [fndg]
Patients [podg]
abciximab [aapp, imft, phsu]
therapy [ftcn]
In [qnco]
Hospital [hcro, mnob]
Medical [ftcn]
Costs [qnco]
eptifibatide [aapp, phsu]
glycoprotein IIb IIIa receptor [aapp, imft, rcpt]
Antagonist [ortf]
abciximab [aapp, imft, phsu]
Aspirin [orch, phsu]
Heparin [bacs, carb, phsu]
Efficacy [qlco]
Reducing [qlco]
short [qlco]
Ischaemic [ftcn]
Complications [patf]
Patients [podg]
ischaemic heart disease [dsyn]
Percutaneous Coronary Intervention [topp]
Aspirin [orch, phsu]
Heparin [bacs, carb, phsu]
High Risk [qlco]
Patients [podg]
Including [ftcn]
Diabetes Mellitus [dsyn]
Benefits [qnco]
abciximab [aapp, imft, phsu]
treatment [ftcn]
abciximab [aapp, imft, phsu]
Therapeutic [topp]
Option [ftcn]
Prevention [topp]
Complications [patf]
Patients [podg]
ischaemic heart disease [dsyn]
